These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab. Demurtas L; Puzzoni M; Giampieri R; Ziranu P; Pusceddu V; Mandolesi A; Cremolini C; Masi G; Gelsomino F; Antoniotti C; Loretelli C; Meriggi F; Zaniboni A; Falcone A; Cascinu S; Scartozzi M Br J Cancer; 2017 Jul; 117(3):315-321. PubMed ID: 28632725 [TBL] [Abstract][Full Text] [Related]
6. Sidedness and TP53 mutations impact OS in anti-EGFR but not anti-VEGF treated mCRC - an analysis of the KRAS registry of the AGMT (Arbeitsgemeinschaft Medikamentöse Tumortherapie). Huemer F; Thaler J; Piringer G; Hackl H; Pleyer L; Hufnagl C; Weiss L; Greil R BMC Cancer; 2018 Jan; 18(1):11. PubMed ID: 29298682 [TBL] [Abstract][Full Text] [Related]
7. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer. László L Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770 [TBL] [Abstract][Full Text] [Related]
8. Anti-EGFR Therapy in Right-Sided Metastatic Colorectal Cancer: Right or Wrong? Weinberg BA J Natl Compr Canc Netw; 2018 Dec; 16(12):1547-1548. PubMed ID: 30545999 [No Abstract] [Full Text] [Related]
9. Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition. Rimassa L; Bozzarelli S; Pietrantonio F; Cordio S; Lonardi S; Toppo L; Zaniboni A; Bordonaro R; Di Bartolomeo M; Tomasello G; Dadduzio V; Tronconi MC; Piombo C; Giordano L; Gloghini A; Di Tommaso L; Santoro A Clin Colorectal Cancer; 2019 Jun; 18(2):125-132.e2. PubMed ID: 30846365 [TBL] [Abstract][Full Text] [Related]
10. The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal cancer. Khelwatty S; Essapen S; Bagwan I; Green M; Seddon A; Modjtahedi H Oncotarget; 2017 Jan; 8(5):7666-7677. PubMed ID: 28032593 [TBL] [Abstract][Full Text] [Related]
11. Phase I study of the anti-heparin-binding epidermal growth factor-like growth factor antibody U3-1565 with cetuximab in patients with cetuximab- or panitumumab-resistant metastatic colorectal cancer. Nakajima TE; Boku N; Doi A; Arai H; Mizukami T; Horie Y; Izawa N; Hirakawa M; Ogura T; Tsuda T; Sunakawa Y Invest New Drugs; 2020 Apr; 38(2):410-418. PubMed ID: 31020609 [TBL] [Abstract][Full Text] [Related]
12. [EGFR protein is a negative prognostic and predictive factor in wild-type RAS colorectal cancer]. Uhlyarik A; Piurkó V; Pápai Z; Rásó E; Lahm E; Kiss E; Sikter M; Vachaja J; Vízkeleti L; Kenessey I; Tímár J Magy Onkol; 2021 Jun; 65(2):121-127. PubMed ID: 34081760 [TBL] [Abstract][Full Text] [Related]
14. Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy. Llovet P; Sastre J; Ortega JS; Bando I; Ferrer M; García-Alfonso P; Donnay O; Carrato A; Jiménez A; Aranda E; León A; Grávalos C; Cámara JC; Feliú J; Sanchíz B; Caldés T; Díaz-Rubio E Mol Diagn Ther; 2015 Dec; 19(6):397-408. PubMed ID: 26341080 [TBL] [Abstract][Full Text] [Related]
15. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab. Tol J; Dijkstra JR; Klomp M; Teerenstra S; Dommerholt M; Vink-Börger ME; van Cleef PH; van Krieken JH; Punt CJ; Nagtegaal ID Eur J Cancer; 2010 Jul; 46(11):1997-2009. PubMed ID: 20413299 [TBL] [Abstract][Full Text] [Related]
16. Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts. Lee HW; Son E; Lee K; Lee Y; Kim Y; Lee JC; Lim Y; Hur M; Kim D; Nam DH Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31771279 [TBL] [Abstract][Full Text] [Related]
17. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis. Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682 [TBL] [Abstract][Full Text] [Related]
18. The role of miRNA -31-3p and miR-31-5p in the anti-EGFR treatment efficacy of wild-type K-RAS metastatic colorectal cancer. Is it really the next best thing in miRNAs? Sur D; Cainap C; Burz C; Havasi A; Chis IC; Vlad C; Milosevic V; Balacescu O; Irimie A J BUON; 2019; 24(5):1739-1746. PubMed ID: 31786833 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of anti-EGFR monoclonal antibodies combined with different chemotherapy regimens in patients with RAS wild-type metastatic colorectal cancer: A meta-analysis. Sun H; Li Y; Su Y; Wu X; Zhou X; Han J; Li J J Evid Based Med; 2019 Nov; 12(4):300-312. PubMed ID: 31596544 [TBL] [Abstract][Full Text] [Related]
20. Potential use of transrenal DNA for non-invasive monitoring and prognosis of colorectal cancer. Chen W; Liao Y; Yang C; Fang Z; Liu B; Zheng X; Zhou C Biomarkers; 2019 Sep; 24(6):524-529. PubMed ID: 31220949 [No Abstract] [Full Text] [Related] [Next] [New Search]